skip to content

Cambridge Institute for Medical Research


Both ApcinteX and the company’s lead development drug SerpinPC, resulted from a collaboration between CIMR’s Prof. Jim Huntington and haematologist Dr Trevor Baglin (formerly of Cambridge University Hospitals). The results from AP-0101, the first human trial of SerpinPC were presented today at the 14th Annual Congress of the European Association for Haemophilia and Allied Disorders. Neither the Phase 1A study with healthy volunteers, nor the Phase 1B study of people with severe haemophilia reported safety concerns. The effect of SerpinPC treatment on the number of bleeding episodes was also measured as an exploratory endpoint in the patient group, and this too looked encouraging. The trial has progressed to Phase 2, with monthly dosing of patient volunteers for six months to further assess the safety and efficacy of SerpinPC.